Eiko Lifesciences has entered into a Share Subscription Agreement (SSA) with Reflux Pharmaceuticals (RPPL) in connection with the acquisition of up to 19,20,000 Equity Shares being 25.01% Equity stake in RPPL in one or more tranches for a consideration of Rs 7.00 crore.
The said partnership with RPPL would benefit the company in co-developing, marketing and sourcing key Active Pharma Ingredients (APIs) and Speciality Chemicals products. Also, this partnership will help the Company to set its footprints in various Geographic areas.
Reflux Pharmaceuticals is a private limited company involved in the manufacturing and marketing of its own Active Pharmaceutical ingredients and Intermediates (APIs). The various products manufactured by RPPL are Tolfenamic Acid, Flavoxate HCI, Diacerein, Albendazole, Carprofen, Sulindac etc.
Eiko LifeSciences is a leading manufacturer, supplier and exporter of Speciality Chemicals and Pharma Intermediates in India and Globally.
| Company Name | CMP |
|---|---|
| BASF India | 3651.95 |
| Tata Chemicals | 804.85 |
| SRF | 2551.40 |
| Pidilite Inds. | 1364.45 |
| Deepak Nitrite | 1751.80 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: